Amyotrophic lateral sclerosis


Amyotrophic Lateral Sclerosis

Endpoint parameters

Neutrojen A 150 Supraselective (Venoplasty 2x IJV + Intrathecal)

Neutrojen A 150 Proprietary biologic / Bone Marrow derived mononuclear cells (autologous trial)

1Y: 30D, 3M, 6M, 12M Baseline: diagnostic tests, CCSVI, Gadolinium MRI Brain & Spine, CT cerebral venography, tests for recognized genetic mutations; familial ALS, defective LXRA protein production by NR1H3, 25 foot walk test (ambulatory subjects), UV exposure, vitamin D synthesis, SF12, PCS / MCS, ALSFRS, ALSAQ- 5, CGBS Scale,
end-point MRI

Immunosuppression (Microglia), reduction in buildup of glutamate, reduction in ADP/Lactic acid buildup, neurogenesis, revascularization, improved cognitive functions, UV exposure, vitamin D synthesis log, 25 foot walk, upper extremity functions, change in T2 lesion volume (if detected in baseline MRI)

Inclusion criteria: Sporadic Amyotrophic Lateral Sclerosis (ALS); M/F (Ag18-70); Spinal stenosis (Myelopathy) negative, Pulmonary embolism negative (preferable rule-out via CTA), recognized genetic mutations such as ‘familial’ mutations may disqualify patients (autosomal recessive diagnosis)

Our Physicians will walk you through each step of the application!

To learn more..
Inquire Now